Volume : 13, Issue : 03, March – 2026

Title:

EMERGING STRATEGIES TO ENHANCE ORAL BIOAVAILABILITY OF POORLY WATER-SOLUBLE DRUGS: FROM BCS CLASSIFICATION TO ADVANCED DELIVERY SYSTEMS

Authors :

Kumbhar Dnyaneshwari Vitthal*, Khandagale Pranoti Abaso, Lavand Yash Vishal, Vagare Dnyaneshwari Balasaheb

Abstract :

Pharmaceutical nanotechnology has emerged as a powerful approach in modern drug development, addressing critical limitations associated with conventional drug delivery systems such as poor solubility, low bioavailability, and systemic toxicity. Lipid-based and polymeric nanocarriers have gained significant importance due to their ability to enhance drug stability, improve targeted delivery, and provide controlled release. Lipid nanocarriers, including liposomes, solid lipid nanoparticles (SLNs), and nanostructured lipid carriers (NLCs), offer excellent biocompatibility and high drug encapsulation efficiency. Polymeric nanocarriers such as polymeric nanoparticles, micelles, and dendrimers enable sustained release and site-specific targeting. These systems significantly improve therapeutic outcomes while reducing adverse effects and enhancing patient compliance. This review discusses classification, mechanisms, advantages, applications, and future prospects of lipid and polymeric nanocarriers in pharmaceutical sciences.
Keywords: Pharmaceutical nanotechnology, Lipid nanocarriers, Polymeric nanoparticles, Targeted drug delivery, Controlled release, Drug development

Cite This Article:

Please cite this article in press Rahul Ishwara Jadhav et al., Pharmaceutical Nanotechnology In Drug Development: Role Of Lipid And Polymeric Nanocarriers In Improving Safety, Efficacy, And Patient Compliance., Indo Am. J. P. Sci, 2026; 13(03).

REFERENCES:

1. Torchilin VP. Nat Rev Drug Discov. 2014.
2. Zhang L et al. Clin Pharmacol Ther. 2008.
3. Allen TM, Cullis PR. Adv Drug Deliv Rev. 2013.
4. Mukherjee PK. Pharmaceutical nanotechnology. 2019.
5. Patel A et al. J Control Release. 2020.
6. Danaei M et al. Pharmaceutics. 2018.
7. Couvreur P. Adv Drug Deliv Rev. 2013.
8. Peer D et al. Nat Nanotechnol. 2007.
9. Koo OM et al. Int J Nanomedicine. 2005.
10. Parveen S et al. Nanomedicine. 2012.
11. Muthu MS et al. Nanomedicine. 2011.
12. Wang AZ et al. Nat Rev Drug Discov. 2012.
13. Duncan R. Nat Rev Cancer. 2006.
14. Blanco E et al. Nat Biotechnol. 2015.
15. Ferrari M. Nat Rev Cancer. 2005.
16. Langer R. Nature. 1998.
17. Kreuter J. J Control Release. 2001.
18. Alexis F et al. Mol Pharm. 2008.
19. Bae YH, Park K. J Control Release. 2011.
20. Brigger I et al. Adv Drug Deliv Rev. 2002.